Analysis of the more frequent occurrence of multiple myeloma in Eastern Bohemia
Authors:
L. Šolcová 1,3; V. Maisnar 2
Authors place of work:
Oddělení klinické biochemie, Oblastní nemocnice Trutnov a. s.
1; IV. Interní hematologická klinika, Fakultní nemocnice Hradec Králové
2; Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové
3
Published in the journal:
Klin. Biochem. Metab., 29, 2021, No. 4, p. 199-203
Summary
Monoclonal gammopathy are a heterogeneous group of disorders. They are characterized by proliferation of clonal differentiated B-cells producing the monoclonal immunoglobulin (MIG). Monoclonal immunoglobulin consists of both an intact immunoglobulin molecule or also only of its structural component, i.e. light chain kappa or lambda, rarely heavy chain. The most common monoclonal gammopathy is monoclonal gammopathy of unknown (undetermined) significance. Every patient with MGUS should be monitored regularly. In recent years, the early diagnosis of MGUS has become increasingly important due to the frequency of monoclonal gammopathy in general and especially the most serious of them - multiple myeloma. A higher incidence of monoclonal gammopathies and especially MM in Czech Republic is apparent from the available data of the National Cancer Registry. The subject of our communication is the fact, that in East Bohemia region (especially in the Trutnov and Nachod regions), according to these data, the highest frequency of malignant lymphoproliferative disorders is recorded. Therefore, we focused on diagnostics and monitoring over time in patients with MGUS, who were detected by the department of clinical biochemistry of the regional hospital in Trutnov as part of a routine examination. In a 10- year follow-up of patients with newly diagnosed monoclonal gammopathy of undetermined significance we monitored their further development over time and also on the frequency of transformation in malignant lymphoproliferative disorders, especially multiple myeloma in the district Trutnov.
Keywords:
free light chains – Multiple myeloma – monoclonal gammopathy – monoclonal immunoglobulin – monoclonal gammopathy of undetermined significance
Zdroje
1. Kyle R.A. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64: 814-26.
2. Maisnar V., Tichý M. a kol. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1. vydání Nucleus HK, Praha 2012, 129s.
3. Maisnar V. Riziko přechodu monoklonální gamapatie nejasného významu do maligní monoklonální gamapatie. Klin Biochem Metab 2013; 21: 93-6.
4. Kyle R.A., Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573-89.
5. Tichý M. Laboratorní analýza monoklonálních imunoglobulinů Tichý M. Laboratorní analýza monoklonálních imunoglobulinů (paraproteinů). 1. vydání Finidr, Český Těšín 1997, 96s.
6. Rajkumar S.V. Multiple myeloma: update on diagnosis, risk-stratification and management. Am J Hematol 2016; 91: 719-34.
7. Van den Donk N.W.C.J., Mutis T., Poddighe P.J. et al. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol 2016; 38(Suppl.1): 110-22.
8. Landgren O., Kyle R.A., Pfeiffer R. M. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
9. Landgren O., Kyle R.A., Rajkumar S.V. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011; 17: 1243-52.
10. Národní onkologický registr - ÚZIS ČR (https://www.uzis.cz)
11. Tichý M., Vávrová J., Friedecký B., Maisnar V. Přehled metod na stanovení volných lehkých řetězců. Klin Biochem Metab 2008; 16: 93-6.
12. Bradwell A.R. Serum free light chain analysis plus Hevylite. 7th ed. Birmingham: The Binding site Ltd. 2015, 415p.
13. Sandecká V., Hájek R., Pour L. et al. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. Eur J Haematol 2017; 99: 80-90.
14. Kyle R.A., Therneau T.M., Rajkumar S.V. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Eng J Med 2002; 346: 564-9.
15. Kyle R.A., Therneau T.M., Rajkumar S.V. et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859-66.
16. Kyle R.A., Durie B.G.M., Rajkumar S.V. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma, IMWG concensus perpectives risk factors for progression and guidelines for monitoring and management. Leukemie 2010; 24: 1121-7.
17. Kyle R.A., Rajkumar S.V., Therneau T.M. et al. Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma 2005; 5: 257-60.
18. Cesana C., Klersy C., Barbarano L. et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20: 1625-34.
19. Vávrová J., Kušnierová P, Maisnar V, Šolcová L. Doporučení České společnosti klinické biochemie a České myelomové skupiny k laboratorní diagnostice monoklonálních gamapatií. Klin Biochem Metab 2020; 28: 26-34.
20. Hájek R., Maisnar V. et al. Diagnostika a léčba mnohočetného myelomu. Transfúze a hematologie dnes 2018; 24(Suppl.): 151-4.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2021 Číslo 4
Najčítanejšie v tomto čísle
- Use of serum calprotectin as rutine biomarker of bacterial infection
- Urea cycle disorders, Arginine Chloride in the treatment of hyperammonemia
- Monoklonální gamapatie – stále aktuální téma
- Pleural effusion – cytological-energy analysis versus traditional Light’s criteria